Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema
The improvements from Baseline to 6-months seen in the Zephyr Valve group were maintained out to 12-months.
- The improvements from Baseline to 6-months seen in the Zephyr Valve group were maintained out to 12-months.
- Data for the medically managed control group was only available out to 6-months as these patients opted to have the Zephyr Valve procedure after completing the 6-month evaluation.
- This is very important data because patients with severe COPD/emphysema have few treatment options once medications no longer alleviate symptoms.
- The Zephyr Valve is the only endobronchial valve approved for the treatment of this large subset of emphysema patients.